| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q04DX002 (ip) | median survival time | saline | 1.3 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.94 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 2.16 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.24 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.6 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 5.4 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 6.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 9.0 mg/kg/injection | 227.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 10.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 15.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.04 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.62 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.73 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.7 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.88 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.5 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.8 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 7.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 45; 07/07 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |